Physician profile
Rohit Saha
NPI 1033560651
$4,254.16
in general payments reported to CMS, 2019-2025
19 companies · $780 in 2025
The $780 reported for 2025 was more than what 77% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $580 · 2024: $2,894 · 2025: $780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,345 · Travel and Lodging: $910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,344.51 |
| Travel and Lodging | $909.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,510.92 | 2023-2025 | Spravato, Invega Sustenna |
| Alkermes, INC. | $453.05 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Axsome Therapeutics, INC. | $408.94 | 2023-2025 | Auvelity |
| Abbvie INC. | $400.52 | 2023-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $216.06 | 2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Indivior INC. | $215.06 | 2023-2024 | Perseris |
| Tris Pharma INC | $206.60 | 2023-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Teva Pharmaceuticals USA, INC. | $181.99 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $148.09 | 2023-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $135.99 | 2023-2024 | Ingrezza |
| Lundbeck LLC | $120.66 | 2023-2024 | Rexulti |
| Brainsway USA INC | $95.48 | 2025 | Deep Tms |
| Noven Therapeutics, LLC | $37.42 | 2024 | Secuado |
| Corium, LLC | $35.78 | 2023-2025 | Azstarys |
| Biogen, INC. | $20.51 | 2024 | Zurzuvae |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $20.20 | 2025 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $17.24 | 2025 | Hetlioz, Fanapt |
| Supernus Pharmaceuticals, INC. | $15.00 | 2025 | Qelbree |
| Vertical Pharmaceuticals, LLC | $14.65 | 2025 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohit Saha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.